Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, Yesterday

Many patient-facing healthcare professionals are supported by colleagues in the back room who make sure they stay well-supplied. For its May-June 2019 issue, MIMS Pharmacist speaks to Choong Kin Hoe, former logistics pharmacist at Hospital Kuala Lumpur (HKL), about what goes on in the store pharmacy.

Postdiagnosis statin use cuts risk of death in hepatocellular carcinoma

02 Feb 2019

Use of statins following diagnosis of hepatocellular carcinoma (HCC) appears to confer survival advantage, a study reports.

Researchers looked at 15,422 patients with HCC in the VA Central Cancer Registry. They identified statin prescriptions filled prior to and after cancer diagnosis and used time-dependent Cox regression models to estimate mortality risk. Meanwhile, a time-varying exposure was applied to avoid immortal-time bias, with a 3-month lag (following patients from 3 months after cancer diagnosis) to reduce reverse causation.

Of the patients, 14.9 percent used statin following diagnosis. Postdiagnosis statin use was associated with a 15-percent reduction in the risk of cancer-specific mortality (adjusted hazard ratio [aHR], 0.85; 95 percent CI, 0.77–0.93) and an 11-percent reduction in all-cause mortality (aHR, 0.89; 0.83–0.95).

The beneficial effect of postdiagnosis statin use on survival was consistent for HCC patients using both low- and high-dose statins and remained across a range of lag periods (0–12 months after HCC diagnosis).

There was no evidence for effect modification by prediagnosis statin use, presentation or treatment-related factors. Finally, prediagnosis statin use showed no association with mortality.

Statins have been reported to protect against the risk of developing HCC, researchers noted. The present data add to existing literature and suggest that the drug provides survival gains in HCC patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, Yesterday

Many patient-facing healthcare professionals are supported by colleagues in the back room who make sure they stay well-supplied. For its May-June 2019 issue, MIMS Pharmacist speaks to Choong Kin Hoe, former logistics pharmacist at Hospital Kuala Lumpur (HKL), about what goes on in the store pharmacy.